Dante Labs appoints Bob Ragusa to its Board of Directors

– USA, NY –  Dante Labs, a global leader in genomics and precision medicine, today announced the appointment of the COO of Illumina Inc. (NASDAQ: ILMN), Bob Ragusa, to the board of directors.

“As Illumina customers, we have been amazed by Illumina’s global customer support and operational excellence. Bob is responsible for leading these achievements and for supporting clinical and research labs globally. Bob is a life science rockstar and will help us deploy our global commercial and clinical offering for multi-omics and integrated precision medicine. The entire team at Dante Labs is excited to have his leadership and guidance to support our ambitious growth plan.” said CEO Andrea Riposati. 

Mr. Ragusa said, “I am very excited to work with Dante to help bridge from improved genomic tools and scientific discovery to positive impact for patients.”

The appointment of Bob Ragusa as a board member has a great strategic fit with the global scaling and growth aspirations. Dante Labs leverages local labs to develop local domain expertise while connecting all local operations in its global network to have superior collective wisdom in every market.

About Dante Labs

Dante Labs is a global genomic data company building and commercializing a new class of transformative health and longevity applications based on whole-genome sequencing and AI. Our assets include one of the largest private genome databases with research consent, a proprietary software platform designed to unleash the power of genomic data at scale, and proprietary processes which enable an industrial approach to genomic sequencing.

Headquartered in Cambridge, United Kingdom, with a research laboratory in Wolverhampton, Dante Labs supported the UK Government’s urgent requirement to scale-up a high-capacity, highly automated testing solution for Covid-19, including infected patients as well as those with antibodies. Dante Labs was able to deliver by leveraging existing technology that had been developed for whole-genome sequencing.

Dante Labs’ integration of software and data with the actual biology in the labs generates unique insights and enables a continuous feedback loop.
Dante Labs’ acquisition of CCG has created global excellence in precision oncology with the potential of impacting patients worldwide, with a total addressable market of $75 billion.
Dante Labs built a stellar team for population genomics and precision medicine.
Over 40 countries are actively involved in population genomics programs with many more that can benefit from genome-based preventative medicine for their citizens.
Dante Labs serves its customers across 97 countries from clinical laboratories and sequencing centers in the United Kingdom and Italy, with at least two more planned in 2021 to expand its global footprint.

For more information: https://www.dantelabs.com/

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

Talent4Boards Team